<DOC>
	<DOCNO>NCT01288469</DOCNO>
	<brief_summary>Primary Objective : To evaluate effect alirocumab ( SAR236553/REGN727 ) low-density lipoprotein cholesterol ( LDL-C ) level compare placebo co-administered 80 mg atorvastatin 8 week treatment participant LDL-C ≥ 100mg/dL ( ≥ 2.59 mmol/L ) atorvastatin 10 mg . Secondary Objectives : - To evaluate effect alirocumab lipid level comparison placebo , co-administered 80 mg atorvastatin 8 week treatment . - To evaluate efficacy alirocumab co-administered high dose atorvastatin ( 80 mg ) versus atorvastatin 10 mg. - To evaluate safety tolerability alirocumab co-administered 2 different dos atorvastatin . - To evaluate development anti-alirocumab antibody . - To evaluate pharmacokinetics alirocumab .</brief_summary>
	<brief_title>Efficacy Safety Evaluation Alirocumab ( SAR236553/REGN727 ) When Co-administered With High Dose Atorvastatin Patients With Primary Hypercholesterolemia</brief_title>
	<detailed_description>The duration study participation depend status patient screening : - For participant receive atorvastatin 10 mg stable dose least 6 week prior screen , study participation approximately 17 week include screen period 1 week , double-blind treatment period 8 week follow-up period 8 week . - For participant receive lipid lower treatment atorvastatin/ stable dose atorvastatin 10 mg least 6 week prior screen , drug naive participant , study participation approximately 23 week screen period 1 week , run-in treatment period atorvastatin 10 mg 6 week , double-blind treatment period 8 week follow-up period 8 week .</detailed_description>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Inclusion criterion : Participants receive lipidlowering treatment atorvastatin/ stable dose atorvastatin 10 mg least 6 week prior screen , drug naive participant primary hypercholesterolemia likely lowdensity lipoprotein cholesterol ( LDLC ) ≥ 100 mg/dL ( ≥ 2.59 mmol/L ) end 6week runin treatment period atorvastatin therapy OR Participants primary hypercholesterolemia treat stable dose atorvastatin 10 mg least 6 week prior screen likely lowdensity lipoprotein cholesterol ( LDLC ) ≥ 100 mg/dL ( ≥ 2.59 mmol/L ) screen visit . Exclusion criterion : 1 . LDLC &lt; 100 mg/dL ( &lt; 2.59 mmol/L ) Week 1 ( V1 ) : After runin period atorvastatin 10 mg participant receive lipid lower treatment atorvastatin/ stable dose atorvastatin 10 mg least 6 week prior screen period , drug naive participant . OR At first visit participant treat atorvastatin 10 mg stable dose least 6 week prior screen visit . 2 . Participants previously instruct cholesterollowering diet . 3 . Participants type 1 diabetes . 4 . Participants type 2 diabetes treat insulin . 5 . Participants type 2 diabetes HbA1c ≥ 8.5 % screen visit ( consider poorly control ) . 6 . Laboratory finding measure randomization : Triglycerides ( TG ) &gt; 350 mg/dL ( &gt; 3.95 mmol/L ) screen visit . Positive serum urine pregnancy test female childbearing potential . 7 . Pregnant breastfeed woman . 8 . Women childbearing potential effective contraceptive method . The information intend contain consideration relevant Participant 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>10020603</keyword>
</DOC>